Pervasis Therapeutics, Inc.

Pervasis Announces Start of Second Clinical Program, Targeting Peripheral Arterial Disease

Pervasis Announces Start of Second Clinical Program, Targeting Peripheral Arterial Disease

April 7, 2010

CAMBRIDGE, Mass., April 7 /PRNewswire/ Pervasis Therapeutics announced today that it enrolled the first patient in a new Phase 1/2 clinical study exploring the potential of PVS-10200 to prevent restenosis in patients who undergo an angioplasty and stent procedure for the treatment of peripheral arterial disease (PAD).

LS9

LS9’s UltraClean Diesel™ Receives EPA Registration

LS9’s UltraClean Diesel™ Receives EPA Registration

April 13, 2010

Diesel Replacement Offers 85% Reduction in Carbon Footprint

(PRWEB) -- LS9, Inc (http://www.ls9.com)., the Renewable Petroleum Company™, today announced that its UltraClean Diesel™, a diesel replacement product offering an 85% reduction in carbon footprint, was officially registered by the United States Environment Protection Agency (EPA). As a registered fuel, LS9’s UltraClean Diesel™ can be sold commercially in the United States.

Joule Unlimited, Inc.

Joule Closes $30M Funding Round

Joule Closes $30M Funding Round

April 27, 2010

Proceeds to help accelerate the drive of renewable solar fuels from lab to commercialization

Cambridge, Mass. – April 27, 2010 – Joule today announced the closing of a $30 million second round of funding, further strengthening the company’s position as it advances from testing to high-capacity production of renewable diesel fuel starting in 2012. The round includes investments from undisclosed institutional and private sources that joined Flagship Ventures, Joule’s founding venture capital investor.

AVEO Pharmaceuticals, Inc.

AVEO Reports First Quarter 2010 Financial Results

AVEO Reports First Quarter 2010 Financial Results

April 29, 2010

Significant Progress in Development of Lead Product Candidate Tivozanib; 2010 Financial Guidance Provided

CAMBRIDGE, Mass., Apr 29, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.

Advanced Electron Beams, Inc
Oasys Water, Inc.

Two Flagship Companies -- Advanced Electron Beams and Oasys Water -- receive DOE Awards in the Industrial Energy Efficiency Grand Challenge

Two Flagship Companies -- Advanced Electron Beams and Oasys Water -- receive DOE Awards in the Industrial Energy Efficiency Grand Challenge

May 5, 2010

Advanced Electron Beams and Oasys Water have each received awards under the DOE's Industrial Energy Efficiency Grand Challenge. They are two of six Massachusetts companies so honored. The DOE press release is below, and contains links to details of all the wards.


DOE Announces Awardees for the Industrial Energy Efficiency Grand Challenge

Award winners to receive more than $13 million to develop transformational manufacturing processes and technologies

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Receives Milestone Payment from Biogen Idec under Licensing Agreement for ErbB3 Antibody Program

AVEO Pharmaceuticals Receives Milestone Payment from Biogen Idec under Licensing Agreement for ErbB3 Antibody Program

April 14, 2010

Milestone Achieved Through Selection of First ErbB3 Antibody Development Candidate

CAMBRIDGE, Mass., Apr 14, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc. (NASDAQ:BIIB), for the selection of the first humanized antibody development candidate from its ErbB3 program.

Agios Pharmaceuticals, Inc.

Celgene Corporation and Agios Pharmaceuticals Announce Global Strategic Collaboration to Advance Unique Science of Cancer Metabolism

Celgene Corporation and Agios Pharmaceuticals Announce Global Strategic Collaboration to Advance Unique Science of Cancer Metabolism

April 15, 2010

Partnership leverages transformational science at Agios and translational capabilities of Celgene to target areas of significant unmet medical need

Ze-gen, Inc.

Ze-gen Welcomes David Robertson As Vice President of Technology

Ze-gen Welcomes David Robertson As Vice President of Technology

April 28, 2010

BOSTON--(BUSINESS WIRE)-- Ze-gen, Inc., a leading developer and integrator of advanced gasification technology to convert waste streams into synthesis gas, today announced the addition of David Robertson to the Ze-gen team. Mr. Robertson is joining Ze-gen as Vice President of Technology.

Mr. Robertson joins Ze-gen after a 30 year career with BP plc. He will be leading the technology development, project deployment, and operations activities at Ze-gen as they progress commercialization of their gasification process.

Avedro, Inc.

Avedro Receives the European Union’s CE Mark for its Vedera™ Ophthalmic Device

Avedro Receives the European Union’s CE Mark for its Vedera™ Ophthalmic Device

April 20, 2010

The company prepares for immediate commercial launch throughout Europe and Asia

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc. today announced its Vedera™ System for performing the Keraflex® procedure has received the European Union’s CE Mark. The CE Mark certifies the Vedera has met the EU’s health and safety standards and opens the door to commercialization across the European Economic Community and in other countries recognizing the CE Mark.

Joule Unlimited, Inc.

Solar Fuel Pioneered by Joule Named among World’s 10 Most Important Emerging Technologies

Solar Fuel Pioneered by Joule Named among World’s 10 Most Important Emerging Technologies

April 21, 2010

Breakthrough platform for direct conversion of sunlight into renewable diesel earns Joule a place among the prestigious Technology Review TR10 for 2010